title: Effects of maropitant in cats receiving dexmedetomidine and morphine.
abstract: OBJECTIVE To evaluate the effects of maropitant in cats receiving dexmedetomidine and morphine. DESIGN Randomized controlled trial. ANIMALS 66 healthy female domestic shorthair cats. PROCEDURES Cats were randomly assigned to receive maropitant (1 mg/kg [0.45 mg/lb], SC; maropitant group; n = 32) or saline (0.9% NaCl) solution (0.1 mL/kg [0.045 mL/lb], SC; control group; 34) 20 hours before IM administration of dexmedetomidine (20 μg/kg [9.1 μg/lb]) and morphine (0.1 mg/kg). Following administration of dexmedetomidine and morphine, the incidences of emesis, retching, and signs of nausea (sialorrhea and lip licking) were compared between the 2 groups. The aversive behavioral response of each cat to injection of maropitant or saline solution was scored on a visual analogue scale by each of 4 observers who were unaware of the treatment administered. RESULTS Only 1 of 32 cats in the maropitant group vomited, whereas 20 of 34 control cats vomited. The incidences of emesis and retching for the maropitant group were significantly lower than those for the control group. The incidence of signs of nausea did not differ between the 2 groups. Visual analogue scale scores for the maropitant group were significantly higher than those for the control group. CONCLUSIONS AND CLINICAL RELEVANCE Results of the present study indicated that administration of maropitant to healthy cats approximately 20 hours prior to administration of dexmedetomidine and morphine significantly decreased the incidence of emesis but did not decrease the incidence of signs of nausea. However, maropitant appeared to cause substantial discomfort when injected SC.
authors.forename: Manuel
authors.initials: M
authors.lastname: Martin-Flores
authors.forename: Daniel M
authors.initials: DM
authors.lastname: Sakai
authors.forename: McKenzie M
authors.initials: MM
authors.lastname: Learn
authors.forename: Alicia
authors.initials: A
authors.lastname: Mastrocco
authors.forename: Luis
authors.initials: L
authors.lastname: Campoy
authors.forename: Jordyn M
authors.initials: JM
authors.lastname: Boesch
authors.forename: Robin D
authors.initials: RD
authors.lastname: Gleed
mesh_terms: D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000009:adverse effects; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects; D000818:Animals; D000932:Antiemetics / Q000008:administration & dosage / Q000627:therapeutic use*; D002371:Cat Diseases / Q000139:chemically induced*; D002415:Cats; D020927:Dexmedetomidine / Q000008:administration & dosage / Q000009:adverse effects; D004347:Drug Interactions; D005260:Female; D007273:Injections, Intramuscular / Q000662:veterinary; D007279:Injections, Subcutaneous / Q000662:veterinary; D009020:Morphine / Q000008:administration & dosage / Q000009:adverse effects; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control / Q000662:veterinary; D011812:Quinuclidines / Q000008:administration & dosage / Q000627:therapeutic use*; D016037:Single-Blind Method; D064232:Visual Analog Scale; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control / Q000662:veterinary*
chemical_list: D018712:Analgesics, Non-Narcotic; D000701:Analgesics, Opioid; D000932:Antiemetics; D011812:Quinuclidines; C518176:maropitant; D020927:Dexmedetomidine; D009020:Morphine